In a nutshell This study evaluated the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple-negative breast cancer (TNBC). This study concluded that the combination of taxanes and chemotherapy is effective with manageable side effects in these patients. Some background TNBC is a subtype of BC that tests...
Read More
In a nutshell The study compared the effectiveness and safety of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) combined therapy with nab-paclitaxel alone in patients with triple-negative breast cancer (TNBC). The study found that combined therapy was more effective than single therapy but it had more serious side effects in these...
Read More
In a nutshell This study evaluated the effectiveness and safety of elacestrant (RAD1901) versus standard hormonal therapy in patients with estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that elacestrant significantly improved survival without cancer worsening with manageable side effects in these...
Read More
Each year in the United States, approximately 264,000 women and 2,400 men are diagnosed with breast cancer. Of those people, about 30% will go on to develop metastatic breast cancer (cancer that has spread beyond the breast, often to the brain, lungs, bones, or liver). Biopsies of breast cancer tissue determine if the surface of the cancer cells...
Read More
In a nutshell This study reported the long-term effectiveness and safety of adding carboplatin (Paraplatin) with or without veliparib (ABT-888) to standard chemotherapy given before surgery (neoadjuvant chemotherapy; NACT) in patients with early-stage triple-negative breast cancer (TNBC). The data showed that the addition of carboplatin to standard NACT...
Read More
In a nutshell This study evaluated the long-term effectiveness of adding ribociclib (Kisqali) to endocrine (hormone) therapy in pre-/perimenopausal patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding ribociclib to hormone therapy significantly improved survival outcomes than hormone...
Read More
In a nutshell This study compared the effectiveness of adding immunotherapy (IT) to chemotherapy (CT) for the treatment of patients with metastatic triple-negative breast cancer (TNBC). The data showed that the addition of IT to CT significantly improved survival without cancer worsening. However, IT plus CT combination did not...
Read More
In a nutshell This study investigated whether the combination of hormonal therapy and cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (Ibrance) was effective in advanced breast cancer in a real-world practice. The authors found that this treatment has similar safety and effectiveness in these patients as shown in clinical trials. Also,...
Read More
In a nutshell This study compared the effectiveness and safety of extended therapy with letrozole (LET; Femara) for 5 years versus the standard therapy of 2-3 years for the treatment of postmenopausal women with early-stage breast cancer (BC). The data showed that extended treatment with LET for 5 years significantly improved the survival outcomes...
Read More
In a nutshell This study compared the effectiveness and safety outcomes of platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) for the treatment of patients with early-stage triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was associated with good outcomes with reduced side effects compared with...
Read More
In a nutshell This study looked at the use of olaparib (Lynparza) treatment for patients with high risk, BRCA1/2-positive, HER2-negative breast cancer (BC). The authors found that in patients with BRCA1/2-positive BC, olaparib after local treatment improved the outcomes of these patients. Some background BC is one of the most common cancers...
Read More
In a nutshell This study evaluated the association between patient-reported outcomes (PROs) and survival outcomes in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (BC) treated with abemaciclib (Verzenio). The data showed that the PROs could be a predictor of survival benefits in these patients. Some...
Read More
